acc1051 |
cdc2 |
phosphorylation |
Tyr15 |
human |
Prostate Cancer |
DU145 |
Gallic acid |
Associated |
4.0 |
17172433
|
acc1052 |
Cdc25A |
phosphorylation |
Ser17 |
human |
Prostate Cancer |
DU145 |
Gallic acid |
Associated |
4.0 |
17172433
|
acc1053 |
Cdc25C |
phosphorylation |
Ser216 |
human |
Prostate Cancer |
DU145 |
Gallic acid |
Associated |
4.0 |
17172433
|
acc1054 |
AKT |
phosphorylation |
Ser473 |
human |
Hepatocellular Carcinoma |
SK-HEP-1 |
Imatinib + GNF5 |
Associated |
4.0 |
30671399
|
acc1055 |
EGFR |
phosphorylation |
Tyr845 |
human |
Colorectal Cancer |
SW620 |
Ganglioside + CD82 OV |
Associated |
4.0 |
33000220
|
acc1056 |
EGFR |
phosphorylation |
Tyr1045 |
human |
Colorectal Cancer |
SW620 |
Ganglioside + CD82 OV |
Associated |
4.0 |
33000220
|
acc1057 |
EGFR |
phosphorylation |
Tyr1173 |
human |
Colorectal Cancer |
SW620 |
Ganglioside + CD82 OV |
Associated |
4.0 |
33000220
|
acc1058 |
ER |
phosphorylation |
Ser118 |
human |
Breast Cancer |
|
Gefitinib + Anastrozole |
Associated |
4.0 |
15925816
|
acc1059 |
EGFR |
phosphorylation |
Tyr845 |
human |
Breast Cancer |
|
Gefitinib + Anastrozole |
Associated |
4.0 |
15925816
|
acc1060 |
AKT |
phosphorylation |
Ser473 |
human |
Breast Cancer |
SUM159 |
Gefitinib |
Impairing |
5.0 |
21660955
|
acc1061 |
AKT |
phosphorylation |
Ser473 |
human |
Breast Cancer |
SUM 149 |
Gefitinib |
Impairing |
5.0 |
21660955
|
acc1062 |
AKT |
phosphorylation |
Ser473 |
human |
Breast Cancer |
SUM229 |
Gefitinib |
Impairing |
5.0 |
21660955
|
acc1063 |
AKT |
phosphorylation |
Ser473 |
human |
Myeloma |
XG-1 |
Genistein |
Associated |
4.0 |
19107739
|
acc1064 |
AKT |
phosphorylation |
Ser473 |
human |
Myeloma |
RPMI8226 |
Genistein |
Associated |
4.0 |
19107739
|
acc1065 |
histone H3 |
methylation |
Lys9 |
human |
Prostate Cancer |
LNCaP |
Genistein |
Associated |
3.0 |
18431742
|
acc1066 |
histone H3 |
methylation |
Lys9 |
human |
Prostate Cancer |
PC3 |
Genistein |
Associated |
3.0 |
18431742
|
acc1067 |
AKT |
phosphorylation |
Ser473 |
human |
Hepatocellular Carcinoma |
SK-HEP-1 |
Glycyrrhizic acid |
Associated |
4.0 |
32054305
|
acc1068 |
ERK1 |
phosphorylation |
Thr202 |
human |
Hepatocellular Carcinoma |
SK-HEP-1 |
Glycyrrhizic acid |
Associated |
4.0 |
32054305
|
acc1069 |
ERK2 |
phosphorylation |
Tyr187 |
human |
Hepatocellular Carcinoma |
Hep3B |
Glycyrrhizic acid |
Associated |
4.0 |
32054305
|
acc1070 |
EGFR |
phosphorylation |
Tyr1069 |
human |
Hepatocellular Carcinoma |
Hep3B |
Glycyrrhizic acid |
Associated |
4.0 |
32054305
|
acc1071 |
ERK1 |
phosphorylation |
Tyr204 |
human |
Hepatocellular Carcinoma |
SK-HEP-1 |
Glycyrrhizic acid |
Associated |
4.0 |
32054305
|
acc1072 |
ERK2 |
phosphorylation |
Thr185 |
human |
Hepatocellular Carcinoma |
SK-HEP-1 |
Glycyrrhizic acid |
Associated |
4.0 |
32054305
|
acc1073 |
ERK2 |
phosphorylation |
Tyr187 |
human |
Hepatocellular Carcinoma |
SK-HEP-1 |
Glycyrrhizic acid |
Associated |
4.0 |
32054305
|
acc1074 |
EGFR |
phosphorylation |
Tyr1069 |
human |
Hepatocellular Carcinoma |
SK-HEP-1 |
Glycyrrhizic acid |
Associated |
4.0 |
32054305
|
acc1075 |
AKT |
phosphorylation |
Ser473 |
human |
Hepatocellular Carcinoma |
Hep3B |
Glycyrrhizic acid |
Associated |
4.0 |
32054305
|
acc1076 |
ERK1 |
phosphorylation |
Thr202 |
human |
Hepatocellular Carcinoma |
Hep3B |
Glycyrrhizic acid |
Associated |
4.0 |
32054305
|
acc1077 |
ERK1 |
phosphorylation |
Tyr204 |
human |
Hepatocellular Carcinoma |
Hep3B |
Glycyrrhizic acid |
Associated |
4.0 |
32054305
|
acc1078 |
ERK2 |
phosphorylation |
Thr185 |
human |
Hepatocellular Carcinoma |
Hep3B |
Glycyrrhizic acid |
Associated |
4.0 |
32054305
|
acc1079 |
ERK1 |
phosphorylation |
Thr202 |
human |
Leukemia |
CML-iPSCs |
Imatinib |
Impairing |
5.0 |
22592606
|
acc1080 |
ERK1 |
phosphorylation |
Tyr204 |
human |
Leukemia |
CML-iPSCs |
Imatinib |
Impairing |
5.0 |
22592606
|
acc1081 |
ERK2 |
phosphorylation |
Thr185 |
human |
Leukemia |
CML-iPSCs |
Imatinib |
Impairing |
5.0 |
22592606
|
acc1082 |
ERK2 |
phosphorylation |
Tyr187 |
human |
Leukemia |
CML-iPSCs |
Imatinib |
Impairing |
5.0 |
22592606
|
acc1083 |
AKT |
phosphorylation |
Ser473 |
human |
Leukemia |
CML-iPSCs |
Imatinib |
Impairing |
5.0 |
22592606
|
acc1084 |
JNK |
phosphorylation |
Thr183 |
human |
Leukemia |
CML-iPSCs |
Imatinib |
Impairing |
5.0 |
22592606
|
acc1085 |
JNK |
phosphorylation |
Tyr185 |
human |
Leukemia |
CML-iPSCs |
Imatinib |
Impairing |
5.0 |
22592606
|
acc1086 |
beta-catenin |
phosphorylation |
Ser33 |
mouse |
Melanoma |
B16 |
Imidazole |
Associated |
4.0 |
20604839
|
acc1087 |
beta-catenin |
phosphorylation |
Ser37 |
mouse |
Melanoma |
B16 |
Imidazole |
Associated |
4.0 |
20604839
|
acc1088 |
beta-catenin |
phosphorylation |
Thr41 |
mouse |
Melanoma |
B16 |
Imidazole |
Associated |
4.0 |
20604839
|
acc1089 |
Bcl-2 |
phosphorylation |
Ser70 |
human |
Hepatocellular Carcinoma |
BEL-7402 |
3-Bromopropionylamino benzoylurea (JIMB01) |
Associated |
4.0 |
12754105
|
acc1090 |
c-FLIP |
phosphorylation |
unclear |
human |
Glioblastoma |
LN-Z2308 |
CH-11 |
Impairing |
5.0 |
17973862
|
acc1091 |
c-FLIP |
phosphorylation |
unclear |
human |
Glioblastoma |
U138 |
CH-11 |
Impairing |
5.0 |
17973862
|
acc1092 |
c-FLIP |
phosphorylation |
unclear |
human |
Melanoma |
WM278 |
CH-11 |
Impairing |
5.0 |
17973862
|
acc1093 |
c-FLIP |
phosphorylation |
unclear |
human |
Melanoma |
WM35 |
CH-11 |
Impairing |
5.0 |
17973862
|
acc1094 |
AKT |
phosphorylation |
Ser473 |
human |
Glioblastoma |
U87 |
KU-60019 |
Associated |
4.0 |
19808981
|
acc1095 |
AKT |
phosphorylation |
Thr308 |
human |
Breast Cancer |
BT474 |
Lapatinib |
Impairing |
5.0 |
25590338
|
acc1096 |
ERK1 |
phosphorylation |
Thr202 |
human |
Breast Cancer |
BT474 |
Lapatinib |
Impairing |
5.0 |
28744398
|
acc1097 |
ERK1 |
phosphorylation |
Tyr204 |
human |
Breast Cancer |
BT474 |
Lapatinib |
Impairing |
5.0 |
28744398
|
acc1098 |
ERK2 |
phosphorylation |
Thr185 |
human |
Breast Cancer |
BT474 |
Lapatinib |
Impairing |
5.0 |
28744398
|
acc1099 |
ERK2 |
phosphorylation |
Tyr187 |
human |
Breast Cancer |
BT474 |
Lapatinib |
Impairing |
5.0 |
28744398
|
acc1100 |
c-Myc |
phosphorylation |
Ser62 |
human |
Breast Cancer |
BT474 |
Lapatinib |
Impairing |
5.0 |
28744398
|